The cap protein is encoded by the orf2 gene of porcine circovirus type 2 (PCV2) has the main antigen epitope of PCV2 and can form virus-like particles (VLPs), which are expressed in insect cells. PCV2-VLPs can effectively inhibit PCV2 replication as a subunit vaccine. In this study, a robust and reliable fed-batch process was successfully developed for the production of PCV2-VLPs by Sf9 cells. The feeding solution, feeding strategy, and cell density at infection were optimized to maximize the final PCV2-VLPs production yields. The cell density at infection and the volumetric PCV2-VLPs production reached 12 × 10⁶ cells/mL and 110 mg/L, respectively, which yielded 3- and 3.6-fold enhancements compared to the batch culture. The PCV2-VLPs produced in fed-batch culture were not different from the PCV2-VLPs produced in a batch culture in an immunity test. A highly efficient production process was produced for PCV2-VLPs subunit vaccines, which could provide an effective means for the industrial production of PCV2 vaccines.

中文翻译：

---

开发一种简单且高产的补料分批工艺，用于生产猪圆环病毒 2 型病毒样颗粒亚单位疫苗。


cap蛋白由猪圆环病毒2型（PCV2）的orf2基因编码，具有PCV2的主要抗原表位，可以形成病毒样颗粒（VLP），在昆虫细胞中表达。 PCV2-VLPs作为亚单位疫苗可以有效抑制PCV2复制。在这项研究中，成功​​开发了一种稳健可靠的补料分批工艺，用于通过 Sf9 细胞生产 PCV2-VLP。优化补料溶液、补料策略和感染时的细胞密度，以最大限度地提高最终 PCV2-VLP 的产量。感染时的细胞密度和体积PCV2-VLP产量分别达到12×10 ^{6 个}细胞/mL和110mg/L，与分批培养相比，其产量提高了3倍和3.6倍。在免疫测试中，补料分批培养中产生的PCV2-VLP与分批培养中产生的PCV2-VLP没有不同。建立了PCV2-VLPs亚单位疫苗的高效生产工艺，为PCV2疫苗的工业化生产提供了有效手段。